Title : Efficacy of pharmacological and non-pharmacological therapies in reducing the disease progression in patients with Alzheimer's disease and Vascular Dementia: A systematic review and network meta-analysis of randomized control trials
Abstract:
Background: Alzheimer's disease (AD) and vascular dementia (VaD) are progressive neurodegenerative conditions characterized by functional impairment and reduced quality of life. Despite extensive research, effective treatments for these conditions remain elusive. While pharmacological interventions (PIs) like cholinesterase inhibitors are common, their impact on disease progression is minimal. Non- pharmacological interventions (NPIs), including computerised cognitive training (CCT) and cognitive stimulation therapy (CST), have gained attention as potential adjunctive therapies. However, the comparative effectiveness of NPIs to PIs remains unclear.
Methods: This meta-analysis was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines 2020, and the review protocol was registered in PROSPERO (Prospective Register of Systematic Reviews) CRD42024590061. Databases like PUBMED, Google Scholar, and COCHRANE Library were hand-searched for RCTs. A systematic search using MeSH (Medical Subject Headings) was done. Covidence software was used for screening, selection of articles and data extraction.
Heterogeneity among the studies was examined using the Higgins I2 test, where I2 < 25% is considered to be low risk, ≥ 50% as moderate risk, and ≥ 75% as high risk. Random-effect models were used for the meta-analysis as I2 values were ≥ 50%. Quality assessment and risk of bias were assessed using the Cochrane risk of bias tool.
Results: A total of 2,426 studies were identified, which were screened for full-text, and 827 studies were screened to fit the selection criteria. Thirty-five studies that met the selection criteria were taken for qualitative synthesis. Four different outcomes were measured using standard scales, respectively. We found that Donepezil had a significant positive effect on the cognitive function of patients with both AD and VaD (MD = 3.37, 95% CI:0.40, 6.35, p<0.05).
Conclusion: MMSE scores were assessed for all the studies (n= 1,372) before and after the intervention. MMSE scores in studies analyzing the effectiveness of PIs (n= 1,128) in patients with AD and VaD showed statistically significant improvement in cognitive outcomes in IG. Hence use of DONEPEZIL proves to have promising effects in improving patient outcomes. NPIs are particularly effective for patients with mild disease. In contrast, PIs tend to show more benefits in moderate to severe disease.
